Specify a stock or a cryptocurrency in the search bar to get a summary
XORTX Therapeutics Inc
XRTXXORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada. Address: 3710 ? 33rd Street NW, Alberta Beach, AB, Canada, T2L 2M1
Analytics
WallStreet Target Price
12.09 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures XRTX
Dividend Analytics XRTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History XRTX
Stock Valuation XRTX
Financials XRTX
Results | 2019 | Dynamics |